Why the study?
Do third-generation oral contraceptives containing desogestrel or gestodene differ from levonorgestrel-containing oral contraceptives in their effects on cardiovascular disease?
Do third-generation oral contraceptives containing desogestrel or gestodene differ from levonorgestrel-containing oral contraceptives in their effects on cardiovascular disease?
When counseling oral contraceptive users, the potentially reduced risk of highly fatal arterial disease with third-generation formulations should be weighed against the reported increased risk of less fatal venous thromboembolism.
Answers are grounded in this paper and cite their sources.
May inform OC counseling on arterial vs venous risks; leaves open net cardiovascular safety pending rigorous trials.
In response to unpublished data revealing a doubling of venous thromboembolism risk with oral contraceptives (OCs) containing desogestrel or gestodene compared with levonorgestrel, the UK Committee on Safety of Medicines advised physicians that women taking these third-generation OCs should be switched to another formulation. There are indications, however, that the studies on which this recommendation was based were flawed by prescriber bias and confounding. In addition, laboratory measures of thrombosis and fibrinolysis do not indicate a shift toward a thrombotic state associated with the newer progestogens. Moreover, desogestrel and gestodene OCs have been associated with a reduced risk of arterial disease when compared to levonorgestrel-containing OCs. Since the mortality associated with acute myocardial infarction is almost 50%, compared with 1-2% for venous thromboembolism, this information should be considered when counseling OC users about their risk of cardiovascular disease. Although the European Union Committee on Proprietary Medicinal Products has taken the position that all OCs are contraindicated in women with current or past cardiovascular disease, unlike the UK Committee, it has not made any specific recommendations about the suitability or non-suitability of the third-generation OCs.
No takes yet. Share an insight, caveat, or question.
David Crook (1997) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: